Graft versus host disease · 5 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ibrutinib monotherapy Variant #01 | — | R 80 133 | 28d | ~41.3 mo | ~30.3 mo | ~45 | ~R 3 605 978 PFS proxy · indirect | 17 |
Ruxolitinib monotherapy Variant #01 | — | R 60 650 | 28d | — | — | — | — | 2 |
Cyclosporine and Prednisone Variant #01 | — | R 46 480 | 56d | — | — | — | — | — |
Prednisone monotherapy Variant #11 | — | R 22 | 7d | ~2.2 mo | ~14.1 mo | ~10 | ~R 215 PFS proxy · indirect | 8 |
Belumosudil monotherapy Variant #01 Partial | — | — | 28d | — | — | — | — | — |
5 of 5 regimens shown